FREDERICK W. DRISCOLL - Corporate Board Profile

Cellectar Biosciences, Inc.

Filing Date	Source Excerpt
2017-04-25	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Our Board concluded that Mr. Driscoll should serve as a director because of his significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background.
2018-04-23	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University.
2018-06-11	Name and Address of Beneficial Owner Frederick W. Driscoll Outstanding — Right to Acquire 3,333 Total 3,333 *.
2019-04-29	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma, MEI Pharma and NantKwest. Mr. Driscoll chairs the Audit Committee and our Board concluded that Mr. Driscoll should serve as a director because of his significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background.
2020-04-28	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma, MEI Pharma and NantKwest. Mr. Driscoll chairs the Audit Committee and our Board concluded that Mr. Driscoll should serve as a director because of his significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background.
2021-01-19	Frederick W. Driscoll
2021-05-13	Mr. Driscoll served as CFO at multiple biopharmaceutical companies and earned a Bachelor’s degree in accounting and finance from Bentley University.
2022-04-29	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma and MEI Pharma. Mr. Driscoll chairs the Audit Committee and is a member of the Compensation Committee. Mr. Driscoll’s significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background make him a highly qualified member of our Board of Directors.
2023-04-28	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University... Mr. Driscoll’s significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background make him a highly qualified member of our Board of Directors.
2023-10-02	Frederick W. Driscoll ... No mention of software or technical qualifications.
2024-04-26	Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma and MEI Pharma. Mr. Driscoll’s significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background make him a highly qualified member of our Board of Directors.

Filing Date

Source Excerpt

2017-04-25

Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Our Board concluded that Mr. Driscoll should serve as a director because of his significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background.

2018-04-23

Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University.

2018-06-11

Name and Address of Beneficial Owner Frederick W. Driscoll Outstanding — Right to Acquire 3,333 Total 3,333 *.

2019-04-29

Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma, MEI Pharma and NantKwest. Mr. Driscoll chairs the Audit Committee and our Board concluded that Mr. Driscoll should serve as a director because of his significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background.

2020-04-28

2021-01-19

Frederick W. Driscoll

2021-05-13

Mr. Driscoll served as CFO at multiple biopharmaceutical companies and earned a Bachelor’s degree in accounting and finance from Bentley University.

2022-04-29

Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma and MEI Pharma. Mr. Driscoll chairs the Audit Committee and is a member of the Compensation Committee. Mr. Driscoll’s significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background make him a highly qualified member of our Board of Directors.

2023-04-28

Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University... Mr. Driscoll’s significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background make him a highly qualified member of our Board of Directors.

2023-10-02

Frederick W. Driscoll ... No mention of software or technical qualifications.

2024-04-26

Mr. Driscoll earned a Bachelor’s degree in accounting and finance from Bentley University. Mr. Driscoll is a member of the board of directors of Cue Biopharma and MEI Pharma. Mr. Driscoll’s significant corporate management and board experience at multiple biotechnology companies as well as his strong financial background make him a highly qualified member of our Board of Directors.

ImmunityBio, Inc.

Filing Date	Source Excerpt
2018-04-24	We believe that Mr. Driscoll is qualified to serve as a member of our board of directors because of his extensive experience and knowledge in the healthcare industry and his significant financial and accounting background.
2019-04-26	We believe that Mr. Driscoll is qualified to serve as a member of our board of directors because of his extensive experience and knowledge in the healthcare industry and his significant financial and accounting background.
2020-04-24	We believe that Mr. Driscoll is qualified to serve as a member of our board of directors because of his extensive experience and knowledge in the healthcare industry and his significant financial and accounting background.

Filing Date

Source Excerpt

2018-04-24

We believe that Mr. Driscoll is qualified to serve as a member of our board of directors because of his extensive experience and knowledge in the healthcare industry and his significant financial and accounting background.

2019-04-26

2020-04-24

MEI Pharma, Inc.

Filing Date	Source Excerpt
2018-10-11	Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.
2019-10-23	Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.
2020-10-27	Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.
2021-10-28	Mr. Driscoll earned a bachelor’s degree in Accounting and Finance from Bentley University. He has served as CFO and CEO in pharmaceutical companies and is an audit committee financial expert.
2022-10-27	Mr. Driscoll earned a bachelor’s degree in Accounting and Finance from Bentley University.
2023-11-08	Mr. Driscoll earned a bachelor’s degree in Accounting and Finance from Bentley University and has served as CFO and CEO in pharmaceutical companies.
2024-12-20	Mr. Driscoll earned a B.S. in Accounting and Finance from Bentley University. We believe that Mr. Driscoll's prior experience as a board member, business experience in the pharmaceutical industry and the area of finance and his status as a financial expert qualify him to serve on the Board.

Filing Date

Source Excerpt

2018-10-11

Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.

2019-10-23

Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.

2020-10-27

Mr. Driscoll earned a bachelor’s degree in accounting and finance from Bentley University.

2021-10-28

Mr. Driscoll earned a bachelor’s degree in Accounting and Finance from Bentley University. He has served as CFO and CEO in pharmaceutical companies and is an audit committee financial expert.

2022-10-27

Mr. Driscoll earned a bachelor’s degree in Accounting and Finance from Bentley University.

2023-11-08

Mr. Driscoll earned a bachelor’s degree in Accounting and Finance from Bentley University and has served as CFO and CEO in pharmaceutical companies.

2024-12-20

Mr. Driscoll earned a B.S. in Accounting and Finance from Bentley University. We believe that Mr. Driscoll's prior experience as a board member, business experience in the pharmaceutical industry and the area of finance and his status as a financial expert qualify him to serve on the Board.

Oncotelic Therapeutics, Inc.

Filing Date	Source Excerpt
2004-04-30	Mr. Driscoll replaced Dr. Nordenvall as our President and Chief Executive Officer upon Dr. Nordenvalls resignation effective June 11, 2002. Prior to that, Mr. Driscoll served as President of Finance and Operations since 2000. Prior to joining us, from 1996 to 2000, Mr. Driscoll worked at Collagenesis Corporation, most recently as Senior Vice President of Finance and Operations. From 1974 to April 1996, he served in various senior management positions at Instrumentation Laboratory.
2005-05-19	Pursuant to the agreement, Mr. Driscoll receives a base salary of $325,000 per year.
2006-04-28	Mr. Driscoll has served as our President and Chief Executive Officer since June 11, 2002. Currently, the President and Chief Executive Officer's base salary is $325,000. He was awarded a bonus of $80,000 in 2005.
2014-04-30	Mr. Driscoll has served as Chairman of our Board of Directors since January 2014. The Audit Committee consists of Ms. Howson, Mr. Driscoll and Dr. McMahon (Chairman). The Compensation Committee consists of Ms. Howson (Chair), Mr. Driscoll and Dr. McMahon. The following table shows the total compensation paid or accrued during the fiscal year ended December 31, 2013 to each of our non-employee directors. Mr. Driscoll will receive a retainer of $90,000 for his service as Chairman.
2015-04-17	The Audit Committee consists of Mr. Driscoll (Chairman), Dr. McMahon, and Ms. Howson. Dr. Schwieterman was a member of the Audit Committee in fiscal year 2014 until the appointment of Mr. Driscoll to the Audit Committee in February 2014. During fiscal year 2014, the Audit Committee held five meetings. Our Audit Committee has the authority to retain and terminate the services of our independent registered public accounting firm, reviews our annual financial statements, considers matters relating to accounting policy and internal controls, and reviews the scope of our annual audits. The Board of Directors has adopted a charter for the Audit Committee, which is reviewed and reassessed annually by the Audit Committee. The Compensation Committee consists of Ms. Howson (Chairperson), Mr. Driscoll, and Dr. McMahon. During fiscal year 2014, the Compensation Committee held four meetings. Dr. Schwieterman was a member of the Compensation Committee in fiscal year 2014 until the appointment of Mr. Driscoll to the Compensation Committee in February 2014. Effective on the date of the Annual Meeting, Dr. Schwieterman will replace Dr. McMahon as a member of the Compensation Committee. The Compensation Committee's roles and responsibilities are set forth in the Compensation Committee's written charter, and include making recommendations to the Board of Directors regarding the compensation philosophy and compensation guidelines for our executives, the role and performance of our executive officers, and appropriate compensation levels for our CEO, which are determined without the CEO present, and other executives based on a comparative review of compensation practices of similarly situated businesses. The Compensation Committee also makes recommendations to the Board regarding the design and implementation of our compensation plans and the establishment of criteria and the approval of performance results relative to our incentive plans. The following table shows the total compensation paid or accrued during the fiscal year ended December 31, 2014 to each of our non-employee directors. Frederick W. Driscoll: Fees Earned or Paid in Cash ($): 67,500; Stock Awards($): 0; Option Awards($): 0; All Other Compensation ($): 40,939; Total: 108,439.
2016-04-25	Mr. Driscoll has served as the Chairman of our Board of Directors since January 2014. The Audit Committee consists of Mr. Driscoll (Chairman), Dr. McMahon, and Ms. Howson. The Compensation Committee consists of Ms. Howson (Chairperson), Mr. Driscoll, and Dr. McMahon. The Nominating and Governance Committee consists of Mr. Driscoll, Ms. Howson, and Dr. McMahon (Chairman).